Alfacip is a prescription medication that contains alfacalcidol as its sole active ingredient. Alfacalcidol is a synthetic analogue of vitamin D₃ (1α-hydroxyvitamin D₃) that is already partially activated, allowing the body to use it without the renal conversion required for cholecalciferol. The product is supplied as hard capsules in two strengths: 0.25 µg and 0.5 µg. In Hong Kong, Alfacip is classified as a prescription (Rx) drug and is regulated by the Department of Health’s Drug Office. The medication is intended for adult patients who require vitamin D supplementation for bone-related conditions.
Alfacalcidol mimics the biological actions of the active form of vitamin D, calcitriol. After oral absorption, it binds to vitamin D receptors (VDR) located in intestinal cells, bone, and the kidney. This binding enhances calcium and phosphate absorption from the gastrointestinal tract and promotes proper bone mineralization. In addition, alfacalcidol suppresses excess secretion of parathyroid hormone (PTH), which helps reduce bone turnover in conditions such as renal osteodystrophy. The drug’s onset of action is usually within a few days, with peak effects on serum calcium occurring after approximately 12-24 hours. Its biological half-life is roughly 20-30 hours, supporting once-daily dosing.
Alfacip is approved for the following indications:
These uses are supported by regulatory approvals in many jurisdictions and by clinical guidelines that recommend vitamin D analogues for patients with impaired renal activation of vitamin D or at high fracture risk. In Hong Kong, prescribing follows the same clinical criteria used by the Hong Kong Society of Nephrology and the Hong Kong Osteoporosis Society.
Regular follow-up visits allow dose titration and early detection of hypercalcemia or other adverse effects.
This article provides educational information about Alfacip and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Alfacip contains alfacalcidol, a vitamin D₃ analogue that is already partially activated, so it does not require the kidney’s 1-α-hydroxylase enzyme for conversion. Regular vitamin D (cholecalciferol) must undergo two hydroxylation steps-first in the liver, then in the kidney-before becoming biologically active. This property makes Alfacip useful for patients with impaired kidney function.
Yes, the two can be combined, but the total calcium intake should be monitored to avoid hypercalcemia. Your doctor may adjust the Alfacip dose or recommend spacing the calcium supplement by a few hours to reduce additive effects on serum calcium.
Serum calcium typically begins to rise within 2-3 days of starting therapy, with the full effect observed after about 1-2 weeks. Regular lab checks are advised to ensure calcium remains within the target range.
Alfacip is generally safe for patients with stable heart conditions, but excess calcium can promote vascular calcification. If you have a history of cardiovascular disease, your physician will monitor calcium and phosphate closely while you are on the medication.
These symptoms may indicate hypercalcemia, a serious side effect. Contact your healthcare provider promptly or seek emergency care if symptoms are severe. Early intervention can prevent complications such as kidney stones or cardiac arrhythmias.
No specific restriction on sunlight is required. Natural UV exposure contributes to endogenous vitamin D synthesis, which can complement the effect of alfacalcidol. However, avoid excessive sun exposure to reduce skin-cancer risk.
Alfacip is frequently prescribed for dialysis patients who suffer from secondary hyperparathyroidism. Dose adjustments are essential, and calcium, phosphate, and PTH levels must be monitored regularly.
For osteoporosis patients, a baseline dual-energy X-ray absorptiometry (DXA) scan is recommended, with follow-up scans every 12-24 months to assess treatment response. In renal osteodystrophy, bone density testing may be less central than monitoring biochemical markers.
The label lists the strength (0.25 µg or 0.5 µg), the inactive ingredients (e.g., lactose, microcrystalline cellulose), the imprint code, and the expiration date. Verify that the imprint matches the product dispensed by your pharmacy.
When traveling, keep the medication in its original container, carry a copy of the prescription, and store it at room temperature. If you cross international borders, be prepared to show the prescription, as vitamin D analogues are prescription-only in most countries.
